In early April 2026, Regeneron Pharmaceuticals received U.S. FDA approval to extend EYLEA HD dosing intervals up to every 20 ...
Regeneron Pharmaceuticals (NasdaqGS:REGN) received FDA approval for extended EYLEA HD dosing intervals for wet age-related macular degeneration and diabetic macular edema. The updated label allows ...
Regeneron Pharmaceuticals has won Food and Drug Administration approval of extended dosing intervals of up to every 20 weeks for its Eylea HD eye drug.
Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements ...
On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ: REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following ...
TARRYTOWN, N.Y., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual ...
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) on Friday reported fourth-quarter adjusted earnings of $11.44 per share, down 5% year-over-year, beating the consensus of $10.71. The company reported ...
Sales of Regeneron Pharmaceuticals' Eylea have declined over the past few quarters due to competition. However, the company launched a new formulation of the medicine that just earned another label ...
A month has gone by since the last earnings report for Regeneron (REGN). Shares have added about 20.2% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the ...
Shares of Regeneron Pharmaceuticals (NASDAQ: REGN), a biotech giant, have been southbound over the past two years as the company navigates challenges to one of its main growth drivers, Eylea. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results